In early breast cancer, therapeutic decisions are based on a number of clinical and pathological factors, including the expression of biomarkers with established clinical utility and validity such as estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and a cellular marker for proliferation (Ki67). This evidence concerns the gene ESR1 and breast cancer.